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Individualisierte Protonenpumpeninhibitor
(PPI)-Gabe bei Patienten mit kombinierter
Thrombozytenaggregationshemmung
(Aspirin und Clopidogrel) und unerwünschten
gastrointestinalen Ereignissen nach perkutaner
koronarer Intervention (PCI): Eine Kohortenstudie
Zusammenfassung. Grundlagen: In einer Patientenkohorte,
welche nach perkutaner koronarer Intervention (PCI) kombi-
nierte Thrombozytenaggregationshemmung (Aspirin und Clopi-
dogrel) erhielt, wurde die Wirksamkeit einer individualisierten
PPI-Gabe zur Reduktion unerwünschter gastrointestinaler
Ereignisse untersucht.
Methodik: Das gastrointestinale Risikofaktorproﬁl und andere
Parameter wurden aus einer speziell angelegten elektronischen
Datenbank extrahiert. Die Patienten wurden via standardisierten
Fragebogen kontaktiert und bei Patienten mit unerwünschten
gastrointestinalen Ereignissen wurde zusätzlich ein strukturiertes
Telefoninterview durchgeführt.
Ergebnisse: In einer Kohorte von 718 Patienten erhielten 87
(12,1%) eine prophylaktische PPI-Therapie. Bei insgesamt 12%
wurden unerwünschte gastrointestinale Ereignisse gefunden,
wobei 18,4% eine PPI-Prophylaxe und 11,1% kein PPI hatten
(OR 1,80, P¼ 0,054). Eine Komedikation mit Steroiden war der
hauptsächliche Risikofaktor für unerwünschte gastrointestinale
Ereignissen (adjusted OR 5,45, P¼ 0,014).
Schlussfolgerungen: Die individualisierte PPI-Therapie basier-
end auf einer Risikoabschätzung für gastrointestinale Blutungs-
ereignisse scheint ein efﬁzientes Instrument zu sein, um
gastrointestinale Ereignisse nach PCI zu minimieren.
Schlüsselwörter:KombinierteThrombozytenaggregationshem-
mung, proton pump inhibitor-Prophylaxe, gastrointestinale
Nebenwirkung, gastrointestinaler Risikofaktor
Summary. Background: We investigated the effect of indivi-
dualised proton pump inhibitors (PPI) prescription on upper
gastrointestinal adverse events in a cohort of patients who re-
ceived combination antiplatelet therapy (aspirin and clopidogrel)
after percutaneous coronary intervention (PCI).
Methods: Upper gastrointestinal risk factors and other para-
meters were extracted from a dedicated electronic database.
Patients were contacted with a standardised questionnaire.
A structured phone interview was performed in all patients with
upper gastrointestinal adverse events.
Results: A cohort of 718 patients on combination therapy
yielded 87 (12.1%) patients with prophylactic PPI treatment.
Upper gastrointestinal adverse events occurred in 18.4% patients
with and in 11.1% patients without prophylactic PPI (OR 1.80,
P¼ 0.054). Co-treatment with corticosteroids was the main iden-
tiﬁable risk factor for upper gastrointestinal adverse events (ad-
justed OR 5.45, P¼ 0.014).
Conclusions: Individualised prescription of PPI-prophylaxis
after PCI in patients on combined antiplatelet therapy based on
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risk assessment for upper gastrointestinal bleeding seems to
represent an effectivemeasure tominimise upper gastrointestinal
adverse events after PCI.
Key words: Combination antiplatelet therapy, prophylactic
proton pump inhibitor, upper gastrointestinal adverse event,
gastrointestinal risk factor
Introduction
Combination antiplatelet therapy has become a
standard therapy in the treatment of acute coronary
syndrome (ACS) and is following percutaneous coro-
nary intervention (PCI) [1].
Two major studies investigated the clinical out-
come in patients receiving aspirin and clopidogrel after
PCI (CURE study) [2] and after ischemic stroke/TIA
(MATCH study) [3] as compared to monotherapy. Al-
though theCURE study showed a better clinical outcome
in the combination therapy arm, both studies had signiﬁ-
cantly higher bleeding rates (includingof gastrointestinal
(GI) origin) in patients receiving the combination treat-
ment of aspirin and clopidogrel [2, 3]. Gastrointestinal
bleeding events occurred in 8.5% (CURE study) and in
7.6% (MATCH study) of patients receiving combination
antiplatelet therapy, respectively [4].
The following risk factors increased upper GI
adverse events (UGI-AE) considerably: History of a
previous gastrointestinal event, age 65 years, antic-
oagulation, corticosteroids and high-dose NSAID or
multiple NSAID or NSAID plus low-dose aspirin [5].
To decrease the incidence of UGI-AE in patients at risk,
proton pump inhibitors (PPI) have been shown to be
beneﬁcial and are indicated as co-treatment of aspirin
or NSAIDs [6–9].
Although previous studies have shown a beneﬁt of
PPI prophylaxis in patients at speciﬁc UGI-bleeding risk
proﬁles and on monotherapy with low-dose aspirin or
clopidogrel, respectively, the indication for a PPI pre-
scription remained at physicians discretion [8–14].
Recently, after a US expert consensus report from
2008, patients with combination antiplatelet therapy
have qualiﬁed to receive a PPI prophylaxis no matter
what UGI-bleeding risk they are at [9]. However, be-
sides immersive costs produced by this new guideline,
there are studies reporting an interaction between
clopidogrel and some PPIs reducing the cardioprotec-
tive effect of clopidogrel [14, 15]. Though recent inves-
tigations could not conﬁrm this thesis, the effect of PPIs
on clopidogrel-based cardioprotection remains to be
clariﬁed [16, 17].
Accordingly, there is a controversy going on about
how far patients on combination antiplatelet therapy
proﬁt from a general PPI prophylaxis. There are little
data that patients in a real-life setting would experience
signiﬁcantly more UGI-AE when PPIs were prescribed
in an individualised rather than a generalised manner
according to UGI-bleeding risk factors. We therefore
conducted a retrospective cohort study at a single
centre in patients on combination antiplatelet therapy
when PPI-prescription was still at physicians discre-
tion. We wanted to investigate the effect of PPI
prescriptions on the UGI-AE rate in patients on combi-
nation antiplatelet therapy after PCI and to analyse if a
general PPI prophylaxis may have been beneﬁcial in
patients at low risk for UGI-AE.
Methods
The study protocol was approved by the ethics
committee of the Kanton St. Gallen.
Database and inclusion criteria
During the period from January 1, 2005 to December 31,
2006, 1500PCIpatientswere assessed.All patient records
were retrieved from our hospital database, in which
patients with coronary angiography and PCI are regis-
tered. Due to current recommendations patients with
non-ST segment elevation myocardial infarction (NSTE-
MI) and ST segment elevation myocardial infarction
(STEMI) received a combination antiplatelet therapy
with aspirin and clopidogrel for twelve months after PCI.
In addition, the following parameters were col-
lected and analysed: prescription of aspirin, clopido-
grel, PPI (Omeprazole, Esomeprazole, Pantoprazole,
Lansoprazole and Rabeprazole), dicumarine and corti-
costeroid use. Medical reports of upper and lower GI
endoscopy within one year after PCI were reviewed.
Endoscopy reports were analysed for indications and
endoscopic lesions (UGI bleeding, ulcers, erosions,
lower GI bleeding).
All patients were hospitalised due to acute coro-
nary syndrome for PCI. During hospitalisation a com-
plete history of gastrointestinal symptoms was taken.
The decision making on PPI prescription as a prophy-
laxis for gastroduodenal ulcer history after PCI was
based on history of upper GI bleeding, chronic
NSAID-use and GERD. The decision was made by the
treating cardiologist or internal specialist.
Exclusion criteria
Patients who declined giving informed consent,
patients with pre-existing GI symptoms not relating to
peptic ulcer disease (e.g. pancreatic cancer and other
malignant diseases) and patients who could not be
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reached for additional interviews in the further analysis
process, were excluded.
Questionnaire
A symptoms-based questionnaire about the 12 months
period after PCI was sent to 1500 patients. The ques-
tionnaire was piloted and adapted in 10 volunteers not
involved in medical issues. Patients were asked to
answer the following questions:
1. Duration of antiplatelet treatment:
a) Did you take Aspirin and Plavix (clopidogrel)
for 1 year after PCI?
b) Did you take either Aspirin or Plavix for 1
year after PCI?
c) Did you take none of them for 1 year after PCI?
2. Did you suffer from any new symptoms in the ﬁrst
year after PCI? If yes, what did you suffer from?
a) Dyspepsia (nausea, stomach pain)
b) Throwing up blood
c) Black stool
d) Anal bleeding
e) Anything else, namely . . . ?
3. What was your reaction to your new symptoms?
a) I did not report my symptoms and they
disappeared.
b) I consulted my family doctor.
c) I went to the hospital.
4. Space for any comment.
Structured telephone interview
To get more precise information, a structured tele-
phone interview was performed in all 137 patients, who
reported either an UGI-AE in the questionnaire or had a
documentation of endoscopic lesions possibly caused
by aspirin/clopidogrel. The aim of this interview was to
clarify misleading symptoms and to stratify the risk
proﬁle of patients with an UGI-AE.
The telephone interview in form of a prompt sheet
contained questions about medication with aspirin,
clopidogrel, dicumarine, PPI, corticosteroids, NSAID,
previous ulcer, previous endoscopies and H. pylori-
infection. Symptoms were inquired in detail, especially
their relation to combination antiplatelet therapy.
Degree of adverse events (AE)
Concerning concomitance and avoiding over-counting,
we analysed UGI-AEs only once per person according to
priority: For UGI-AEs themost severe degreewere ulcers
and erosions including UGI bleeding, followed by hema-
temesis, overt bleeding with black stools and dyspepsia.
Excluded
n = 657 
Death 
n = 54 
Date of death 
unknown 
n = 10 
>1 year after PCI 
n = 23 
<1 year after PCI 
n = 21 
No answer 
n = 528 
Other** 
n = 134 
UGI* 
n = 86 
AE 
n = 185 
No AE 
n = 533 
Other 
intervention 
than PCI 
n = 32
Unwilling to 
participate 
n = 16 
Initial study population
(Patients with PCI from 2005 to 
2006 at the KSSG) 
n = 1500 
Other 
n = 27 
Monotherapy
n = 125 
Included for analysis:
Combination therapy 
n = 718 
No AE
n = 85 
AE
n = 40 
UGI* 
n = 20  
Other** 
n = 36 
Fig. 1: Selection of study population. *UGI¼ ulcer, erosion, upper GI bleeding, overt bleeding and dyspepsia. **Other¼ lower GI bleeding, anal bleeding,
bleeding of other organs, skin and ENT bleeding, dizziness/cardiovascular dysregulation, hypersensitivity, headache, musculoskeletal and not otherwise
speciﬁed AEs
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Primary and secondary endpoint
Primary endpoints were severe adverse events (SAE) of
UGI-AE. SAE were deﬁned as a prolongation of hospi-
talisation, rehospitalisation in relation to an UGI-AE or
endoscopically proven UGI bleeding. Secondary end-
points were the occurrence of any UGI-AE as there were
Tab. 1: Characteristics of the study cohort with combination antiplatelet therapy after PCI
Prophylactic PPI (%)
nD 87
No prophylactic PPI (%)
nD 631
P-value
n
Age, mean (SD) yr 68 (9) 64 (11) < 0.001
Sex ns
Male 61 (70.1) 469 (74.3)
Female 26 (29.9) 162 (25.7)
UGI-AE 16 (18.4) 70 (11.1) ns
Upper GI bleeding (E) 0 (0) 2 (0.3) ns
Ulcer (E) 0 (0) 2 (0.3) ns
Erosion (E) 2 (0.3) 2 (0.3) ns
Black stool 4 (4.6) 15 (2.4) ns
Hematemesis 0 (0) 2 (0.3) ns
Dyspepsia 11 (12.6) 60 (9.5) ns
Bleeding-AE other than UGI-AE 12 (13.8) 92 (14.6) ns
Lower GI bleeding (E) 1 (1.1) 6 (1) ns
Anal bleeding 5 (5.7) 17 (2.7) ns
Bleeding of other organs 0 (0) 5 (0.8) ns
Skin bleeding 6 (6.9) 54 (8.6) ns
ENT* bleeding 1 (1.1) 19 (3) ns
Other AE 6 (6.9) 30 (4.8) ns
Dizziness/cardiovascular dysregulation 0 (0) 9 (1.4) ns
Hypersensitivity 4 (4.6) 8 (1.3) 0.023
Headache 2 (2.3) 3 (0.5) ns
Musculoskeletal 0 (0) 5 (0.8) ns
Others 0 (0) 7 (1.1) ns
UGI-bleeding risk factors
Age>65 yr 53 (61) 282 (44.7) ns
Dicumarine 9 (10.3) 33 (5.2) ns
Corticosteroids 3 (3.4) 6 (1.0) ns
Cardiovascular risk factors
Nicotine (n¼710) 26 (29.9) 218 (34.5) ns
Hypercholesterinemia (n¼712) 85 (97.7) 601 (95.2) ns
Hypertension (n¼712) 69 (79.3) 392 (62.1) 0.002
Diabetes (n¼707) 11 (12.6) 100 (15.8) ns
Family history (n¼ 709) 18 (20.7) 141 (22.3) ns
E endoscopic diagnosis; ns not signiﬁcant; *ENT Ear Nose Throat.
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uncomplicated GI-lesions without bleeding (erosions
and ulcers), typical GI symptoms as dyspepsia and
black stool in patients without endoscopy.
Risk proﬁle
Patients with an UGI-AE were investigated further for
the risk factors age >65 y, concomitant use of steroids,
dicumarine and NSAID, H. pylori infection and previ-
ous peptic disease.
Statistical analysis
Fishers exact test was used to test for signiﬁcant differ-
ences in presence of UGI-AEs by the various risk factors.
Additionally, multiple logistic regression (Hosmer and
Lemeshow [2000]) [18] was used to examine the effect
of all risk factors simultaneously. P-values have not
been adjusted for multiple testing. All analyses were
performed in the R programming language [19].
Results
Exclusion criteria
Among the 1500 patient ﬁles, which were selected
from the cardiologic database, 718 patients with PCI
and combination antiplatelet therapy qualiﬁed for
further analysis. 657 patients were excluded for vari-
ous reasons, as described in detail in Fig. 1.
Additionally, 125 patients were on monotherapy
(¼aspirin or clopidogrel for 12 months). 18.9% of them
had UGI-AE vs 12% with UGI-AE on combination anti-
platelet therapy. Monotherapy did not show a different
spectrum of UGI-AE compared to patients with combi-
nation antiplatelet therapy. They were not considered
for further analyses. Baseline characteristics are given
in Tab. 1.
Primary and secondary endpoints
Primary endpoints (SAE) were observed in 5 patients
(0.7%). All SAEs resulted in prolongation of hospitalisa-
tion. Details of patients (3 male and 2 female) with SAE
are presented in Tab. 2.
Secondary endpoints were found in 81 (11.3%)
patients. 57 were male and 24 female: Erosions (n¼ 4,
0.6%), black stool (n¼ 14, 2.0%), dyspepsia (n¼ 63,
8.8%).
PPI and UGI-AE
UGI-AE occurred in 86 (12.0%) patients. 16 of these
were on prophylactic PPI and 70 had no acid suppres-
sion. There was no difference in the frequency and
severity of UGI-AE in the groups with and without PPI
(p¼ 0.57) and there was no difference in type of PPI,
either.
Considering the entire study cohort (n¼ 718), 87
(12.1%) patients were treated with prophylactic PPI.
In these 87 patients, UGI-AE occurred in 16 (18.4%).
In the group without prophylactic PPI (n¼ 631, 87.9%),
UGI-AE was observed in 70 (11.1%) patients (Tab. 3).
Considering only the data in the group without PPI
prophylaxis the number needed to treat (NNT) with a
prophylactic PPI to prevent one UGI-AE was 14.
Risk factors in patients with prophylactic PPI
medication
Despite co-treatment with prophylactic PPI, UGI-AE
occurred in 16 patients. Table 4 shows their risk factor
proﬁle and PPI dose.
There was no difference in the dose of PPIs be-
tween patients with and without AE. Age >65 y was the
most frequent risk factor and was found in 53 (69%),
second in line was dicumarine with a total of 7 (8%).
Predictive factors for UGI-AE
For the whole study cohort (n¼ 718), the risk factors
age >65 y (326/718, 45.4%), steroids (9/718, 1.2%),
dicumarine (42/718, 5.8%) and prescription of prophy-
lactic PPI (631/718, 87.9%) were analysed. The results of
the logistic regression analysis are given in Tab. 5. This
multivariate analysis demonstrated that patients with
prescription of steroids had a signiﬁcantly higher inci-
dence of UGI-AE. Steroids had a signiﬁcant impact on
the rate of UGI-AE after adjustment for age, dicumarine
Tab. 2: Risk proﬁle of patients with UGI-SAE (nD 5)
Diagnosis Prophylactic
PPI
Age >65
years
Dicumarine NSAID Corticosteroids Ulcer
history
Peptic ulcer* (n¼ 3) 0 2 0 1 0 0
No source** (n¼2) 1*** 2 1 0 0 0
*Two patients had a gastric ulcer, one patient had a duodenal ulcer; **One patient had black stool, one patient had hematemesis but no
endoscopic ﬁnding; ***Double standard dose: Lansoprazole 30mg/40mg of every other PPI.
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and prophylactic PPI, with an OR of 5.45 (CI 1.30–21.35,
P¼ 0.0142). Age> 65 y, dicumarine co-treatment and
lack of prophylactic PPI were not independent risk
factors for UGI-AEs.
In the subgroup analysis of patients with UGI-AE
and without prophylactic PPI (n¼ 70), the presence of
ulcer history, NSAID co-treatment and H.pylori-infec-
tion were not independent risk factors for UGI-AEs.
Discussion
This cohort comprised 718 patients with PCI re-
quiring combination antiplatelet therapy with aspirin
and clopidogrel for at least 12 months after the inter-
vention according to the guidelines of the European
Society of Cardiology [1]. This was an observational
study with the aim to analyse the practice of an indi-
vidualised prescription of PPIs in patients on combina-
tion antiplatelet therapy and to investigate its role in
prevention of UGI-AEs.
The incidence of UGI-AE in this study was
12.0%, including 0.8% endoscopically diagnosed le-
sions (¼UGI bleeding, ulcer, erosion) and 0.7% UGI-
SAE. Previous trials yielded comparable incidences
of UGI-AE: The CURE and the MATCH study had an
incidence of major GI-bleeding episodes (i.e. SAE) of
0.84% and 0.421%, respectively [3, 20]. In a Chinese
multicentre retrospective study on combination an-
tiplatelet therapy, patients developed a comparable
rate of endoscopically proven ulcer and erosion as in
our study, namely 0.8% [21].
Efﬁcacy of PPIs in prevention of UGI-AE has been
conﬁrmed in different studies previously [11, 12,
22–27]. However, a beneﬁcial effect could not be shown
in this study (OR 1.80, 95%CI 0.926–3.352, P¼ 0.05408)
when comparing patients with PPI and those without.
All over, only 87 of 718 (12.1%) patients had prophylac-
tic PPI therapy after PCI. However, this low prescription
rate is in line with three other studies performed in a
similar setting showing rates between 5.7 and 27.6% [11,
12, 28]. In contrast to our observation these studies
showed a signiﬁcant decrease in UGI-AE in patients
with prophylactic PPI. However, these studies differ
from our cohort as regards indication and study popu-
lation: Patients may have beneﬁted more from a PPI
prophylaxis as they had an increased GI risk proﬁle
compared to our cohort since they were signiﬁcantly
older than our patients 72.1 vs 64 yrs [11] and were
more often on enoxaparin during hospitalisation [11,
12]. In addition a large Japanese study [28] was per-
formed in patients with aspirin and thienopyridine
derivates (ticlopidine) instead of clopidogrel and can
therefore not be compared adequately.
The tendency in our cohort study for having a
UGI-AE while being on PPI therapy may be explained
by a selection bias: Patients had PPIs for different
reasons, such as ulcer history, concomitant NSAID-use
and age > 65 y, and were therefore already at increased
risk for bleeding despite acid suppression. This is in
contrary to randomised trials with matching of patients
in a PPI group and a non-PPI group according to their
UGI-bleeding risk [11, 12, 28].
According to previous studies, patients with the
following conditions are at high risk and will possibly
beneﬁt from prophylactic PPI treatment after PCI: pa-
tients with a history of ulcer disease, concomitant
NSAID-use, concomitant Dicumarine-use, H. pylori
infection, and age >65 years [6–9]. In this study, con-
comitant use of corticosteroids was proven to be an
independent risk factor for UGI-AE after adjustment for
Tab. 4: Risk factors and PPI dose in patients with UGI-AE and prophylactic PPI (nD 16)
Age
> 65
Dicumarine Steroids Ulcer history NSAID PPI
standard
dose*
PPI double
standard
dose**
Erosion (n¼ 2) 1 0 0 1 0 1 1
Overt bleeding*** (n¼ 3) 3 2 0 1 0 0 3
Dyspepsia (n¼ 11) 6 2 1 4 3 5 6
*Lansoprazole 15mg/10–20mg of every other PPI; **Lansoprazole 30mg/40mg of every other PPI; ***Black stool, hematemesis.
Tab. 3: Prophylactic PPI therapy in patientswith
versus without UGI-AE in the whole
study population nD 718)
Patients with
UGI-AE
Odds
ratio
(95% CI)
P-value
Yes
(nD86)
No
(nD 632)
Prophylactic
PPI
16
(18.6%)
70
(11.1%)
1.80
(0.93–3.35)
0.05408
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age, dicumarine and absence of PPI treatment (OR-
5.45, 95% CI 1.30–21.35, P¼ 0.0142) and increased the
risk for UGI-AE 3.8-fold. This is in line with the current
literature, showing a 2-fold increased risk for UGI-AE in
patients on long-term NSAID therapy and corticoster-
oids [5, 24].
Conclusion
Patients judged by their physician not to need a
PPI showed a trend for fewer UGI-AE than patients on
PPI therapy. Thus, the need for a PPI prophylaxis as
elucidated individually by GPs based on a risk assess-
ment for UGI-bleeding seems to be an effective mea-
sure to minimise UGI-AE after PCI. Whether patients
with UGI-risk factors were treated inadequately as con-
cerns the dose of PPI and adherence to PPI medication
cannot be precisely answered in this study. An indivi-
dualised prescription practice of PPIs seems to be still
adequate and may prevent an overuse of PPI-therapy
especially in the light of interactions with clopidogrel.
Further prospective studies on the value of a
prophylactic PPI medication in patients at low risk for
UGI-AE should address this question.
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Tab. 5: Adjusted odds ratio for UGI-AE
in the study population (nD 718)
Number of
patients with
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Odds
ratio
P-
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(nD 86)
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Age>65 y 40 (46.5) 46 (7.3) 0.98 (0.62–1.55) 0.9377
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